(Boursier.com) — Ipsen falls back by 2% to 106 euros this Friday, while RBC Capital remains in line on the file by raising its target from 124 to 127 euros. The group announced last month growth in total sales in 2023, up 6.7% at constant exchange rate (3.4% in published data) to €3.127 billion, driven by the performance of growth platforms and the contribution new drugs. The operating margin of the activities which stands at 32% (IFRS operating margin at 26.1%) was achieved in a context of increased investments in ‘R&D’ mainly linked to recent acquisitions. Free cash flow fell by 13% to €710.9 million. The IFRS consolidated net result comes to €647.2 million…
The financial objectives for the year 2024 will involve growth in total group sales of more than 6% at constant exchange rate and an operating margin of around 30% including the impact of four potential launches and a portfolio of reinforced ‘R&D’ products…
Among the other brokers’ opinions, Deutsche Bank retains the file with an adjusted target of 113 euros, while Barclays remains at ‘market weighting’ with a target that climbs to 125 euros.
©2024 Boursier.com